Syndax Pharmaceuticals, Inc.
SNDX
$19.84
$0.763.98%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -49.36M | -42.67M | -68.01M | -60.72M | -71.85M |
| Total Depreciation and Amortization | 5.00K | 4.00K | 3.00K | 3.00K | -- |
| Total Amortization of Deferred Charges | 303.00K | 56.00K | -1.00K | 62.00K | 55.00K |
| Total Other Non-Cash Items | 13.99M | 11.32M | 10.28M | 13.49M | 10.75M |
| Change in Net Operating Assets | 4.79M | -19.05M | -11.76M | -23.38M | -26.75M |
| Cash from Operations | -30.27M | -50.35M | -69.49M | -70.54M | -87.80M |
| Capital Expenditure | -40.00K | -- | -56.00K | -131.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -16.87M | 38.39M | 81.63M | 72.56M | 41.89M |
| Cash from Investing | -16.91M | 38.39M | 81.58M | 72.43M | 41.89M |
| Total Debt Issued | 250.00M | -- | -- | -- | -- |
| Total Debt Repaid | -6.15M | -- | -- | -- | -- |
| Issuance of Common Stock | 8.92M | 7.92M | 5.92M | 6.28M | 551.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 252.77M | 7.92M | 5.92M | 6.28M | 551.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 205.58M | -4.04M | 18.01M | 8.17M | -45.36M |